Novo Nordisk (NVO) Faces Securities Fraud Lawsuit

Rosen Law Firm is representing investors who purchased Novo Nordisk A/S (NVO) securities between May 7 and July 28, 2025. A class action lawsuit alleges Novo Nordisk made misleading statements about its growth potential. Investors have until September 30, 2025, to apply to be lead plaintiff.

The Rosen Law Firm announced a securities fraud class action lawsuit against Novo Nordisk A/S (NVO). The firm alleges that Novo Nordisk misled investors regarding its growth prospects between May 7 and July 28, 2025.

The complaint claims that Novo Nordisk presented overly optimistic statements while concealing negative information about its growth potential. Specifically, the firm alleges that the company downplayed the potential impact of a specific market exception and overestimated the likelihood of patients switching to Novo Nordisk’s branded products.

The lawsuit further contends that Novo Nordisk exaggerated its ability to penetrate specific markets and achieve sustained growth. When the true information became public, the firm argues, investors experienced financial losses.

Investors who purchased NVO securities during the specified period may be eligible for compensation. Rosen Law Firm is seeking a lead plaintiff to represent the interests of all class members in the litigation. The deadline for applying to be the lead plaintiff is September 30, 2025.

Rosen Law Firm encourages investors to choose counsel with a proven track record in securities class actions. They highlight their own extensive experience and success in securing significant settlements for investors, including a record-breaking settlement against a Chinese company. The firm emphasizes its consistent ranking among top securities class action firms.

The firm states that no class has been certified yet, meaning investors are not automatically represented unless they retain counsel. Investors can choose their own legal representation or choose to remain an absent class member. Participation in any potential recovery is not contingent on serving as lead plaintiff.

Interested investors can contact Phillip Kim, Esq. at 866-767-3653 or email case@rosenlegal.com for more information. The Rosen Law Firm also provided additional contact information for further inquiries. The firm’s announcement includes standard legal disclaimers regarding prior results not guaranteeing future outcomes.

Share: X Facebook LinkedIn WhatsApp
Share your love